David Mozley - Endocyte Vice President - Imaging
President
Dr. P. David Mozley, M.D. is no longer the Vice President Imaging of Endocyte, Inc. Dr. Mozley will provide medical and scientific leadership across Endocyte companion imaging agent portfolio. Dr. Mozley has over 25 years of experience using radiopharmaceuticals to diagnose and treat diseases. He is a boardcertified physician in nuclear medicine. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian HospitalWeill Cornell Campus in Manhattan. From 2001 to 2012, Dr. Mozley held multiple positions with progressively increasing responsibilities at Eli Lilly and Merck Co. While at Merck Co., he served as senior imaging lead across therapeutic areas for multicenter trials that used imaging as a major endpoint, chaired the PhRMA Imaging group, and cochaired a technical committee on quantitative imaging for the Radiological Society of North America. He has contributed to the publication of over 100 research reports in the literature on imaging since 2015.
Tenure | 9 years |
Phone | 765 463-7175 |
Web | www.endocyte.com |
Endocyte Management Efficiency
The company has return on total asset (ROA) of (26.4801) % which means that it has lost $26.4801 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2763) %, meaning that it created substantial loss on money invested by shareholders. Endocyte's management efficiency ratios could be used to measure how well Endocyte manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 12.64 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Endocyte has a current ratio of 44.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Endocyte until it has trouble settling it off, either with new capital or with free cash flow. So, Endocyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endocyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endocyte to invest in growth at high rates of return. When we think about Endocyte's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Thomas Fisher | Pebblebrook Hotel Trust | 53 | |
Jeffrey Fowler | BJs Restaurants | 50 | |
Alexander Puchner | BJs Restaurants | 62 | |
Jonathan Stanner | Summit Hotel Properties | 43 | |
Paul Ruiz | Summit Hotel Properties | 58 | |
Greg Dowell | Summit Hotel Properties | 50 | |
Matthew Clark | The Cheesecake Factory | 54 | |
Darrell Ligten | The Wendys Co | 49 | |
Gregory Dowell | Summit Hotel Properties | 52 | |
Robert Stewart | Ark Restaurants Corp | 58 | |
Craig Aniszewski | Summit Hotel Properties | 57 | |
Anthony CPA | Ark Restaurants Corp | 60 | |
Scott Toop | The Wendys Co | 60 | |
Raymond Martz | Pebblebrook Hotel Trust | 54 | |
Christopher Eng | Summit Hotel Properties | 53 | |
David Gordon | The Cheesecake Factory | 59 | |
Keith Carango | The Cheesecake Factory | 62 | |
Jill Peters | The Cheesecake Factory | N/A | |
Cheryl Slomann | The Cheesecake Factory | 58 | |
Carl Mayfield | Park Hotels Resorts | 60 | |
Lon Ledwith | BJs Restaurants | 60 |
Management Performance
Return On Equity | -0.28 | |||
Return On Asset | -26.48 |
Endocyte Leadership Team
Elected by the shareholders, the Endocyte's board of directors comprises two types of representatives: Endocyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endocyte. The board's role is to monitor Endocyte's management team and ensure that shareholders' interests are well served. Endocyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endocyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Hanham, Independent Director | ||
Christopher Leamon, VP of RandD | ||
Marc Kozin, Director | ||
Cooper Russell, Director | ||
Patrick Machado, Director | ||
Alison Armour, Chief Medical Officer | ||
Michael Sherman, CFO and COO | ||
David Mozley, Vice President - Imaging | ||
Michael Brinkley, Vice President - Quality | ||
Katherine Parker, Vice President of Human Resources | ||
Lesley Russell, Independent Director | ||
Keith Brauer, Independent Director | ||
Ron Ellis, Co-Founder, CEO and President and Director | ||
Philip Low, Co-Founder, Chief Scientific Officer and Director | ||
Beth Taylor, Corporate Controller | ||
Fred Middleton, Independent Director | ||
Lesley Cooper, Director | ||
Peter Meldrum, Director | ||
Michael Andriole, CFO | ||
Colin Goddard, Director | ||
Scot Harper, VP of Clinical Operations | ||
Erik Chelius, Vice President - CMC | ||
John Aplin, Independent Chairman of the Board |
Endocyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endocyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.28 | |||
Return On Asset | -26.48 | |||
Profit Margin | 0.0008 % | |||
Operating Margin | (6.07) % | |||
Current Valuation | 1.63 B | |||
Shares Outstanding | 82.1 M | |||
Shares Owned By Insiders | 4.85 % | |||
Shares Owned By Institutions | 92.21 % | |||
Number Of Shares Shorted | 8.34 M | |||
Price To Earning | (4.45) X |
Pair Trading with Endocyte
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endocyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endocyte will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Iron Mountain could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Iron Mountain when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Iron Mountain - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Iron Mountain Incorporated to buy it.
The correlation of Iron Mountain is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Iron Mountain moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Iron Mountain rporated moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Iron Mountain can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Endocyte Stock
If you are still planning to invest in Endocyte check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endocyte's history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stocks Directory Find actively traded stocks across global markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |